Advertisement

Topics

Jnana Therapeutics Inc. Company Profile

15:21 EDT 26th April 2018 | BioPortfolio


News Articles [718 Associated News Articles listed on BioPortfolio]

Jnana Therapeutics Launches with $50M Series A Financing to Target Cell's Metabolic Gates

NewsJnana’s proprietary small molecule platform allows the company to address therapeutic targets rapidly and comprehensively across the SLC transporter family.

Jnana Therapeutics Emerges with $50M to Find Cellular Protein Drugs

Drug discovery startup Jnana Therapeutics has come out of stealth mode with $50 million in funding that it plans to use to search for new drugs that target proteins that move substances across cellula...

Jnana closes $50mm Series A round

Jnana Therapeutics Inc. has launched with $50mm in Series A funding from seed backers Polaris Partners and Avalon Ventures and new investors Versant Ventures, AbbVie Ventures, and Pfizer R&D Innovate....

Abbvie, Pfizer Jump in on Newly-Launched Jnana Therapeutics' $50M Funding Round

Seed funders Polaris Partners and Avalon Ventures were joined in the Series A syndicate by Versant Ventures, AbbVie Ventures, and Pfizer R&D Innovate.

Jnana launches with $50M series A

Jnana Therapeutics Launches With $50 Million Series A Financing to Target the Cell’s Metabolic Gates

Top-tier syndicate backs serial entrepreneur and world-renowned academics Stuart Schreiber and Ramnik Xavier Jnana Therapeutics Inc. today announced a $50 million Series A ...

Global Veterinary Therapeutics Market to Mark CAGR of 6.0% Over Next 10 Years - MarketResearch.biz

MarketResearch.biz announces publication of its recently generated research report titled, "GlobalVeterinary Therapeutics MarketBy Type (Therapeutics Drugs, Therapeutics Vaccines, Feed Additives The...

What You Need to Know About Indalo Therapeutics

Indalo Therapeutics is based in St. Louis and was formed in October 2016 from the merger of Antegrin Therapeutics and Cascadia Therapeutics.

PubMed Articles [403 Associated PubMed Articles listed on BioPortfolio]

Recent developments in intracellular protein delivery.

Protein therapeutics based on transcription factors, gene editing enzymes, signaling proteins and protein antigens, have the potential to provide cures for a wide number of untreatable diseases, but c...

Alternative therapeutics for self-limiting infections-An indirect approach to the antibiotic resistance challenge.

Alternative therapeutics for infectious diseases is a top priority, but what infections should be the primary targets? At present there is a focus on therapies for severe infections, for which effecti...

Introduction to Volume 2 of JOPT Special Issue.

Eyes on New Product Development: Preclinical Research.

Eyes on New Product Development: Preclinical Research.

Clinical Trials [139 Associated Clinical Trials listed on BioPortfolio]

Impact of Ibis on Patients With Advanced COPD

The purpose of this research is to determine if Ibis™, a digital therapeutics solution developed by Senscio Systems, reduces the emergency room visits and hospitalizations of patients wi...

HDL Acute Lipid Optimization in Homozygous Familial Hypercholesterolemia

Assess the effect on coronary atheroma of serial infusions of autologous selectively delipidated HDL/preβ enriched plasma following use of HDL Therapeutics PDS-2™ System

Ontogenesis of the P-Glycoprotein in Human Lymphocytes Influence of HIV and Antiretroviral Therapeutics

The P-glycoprotein (P-gp) is a membranous transporter that modulates the intracellular concentrations of many drugs and plays thus a major role in the efficacy of the therapeutics that act...

A Trial to Find Safe and Active Doses of an Investigational Drug CX-072 for Patients With Solid Tumors or Lymphomas

The purpose of this first-in-human study of CX-072 is to characterize the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD) and antitumor activity of CX-072 administered i...

A Study of BBI503 in Combination With Selected Anti-Cancer Therapeutics in Adult Patients With Advanced Cancer

This is an open label, multi-center, Phase 1/2 study of BBI503 administered in combination with selected anti-cancer therapeutics in adult patients with advanced cancer. The goal of the st...

Companies [1216 Associated Companies listed on BioPortfolio]

Jnana Therapeutics Inc.

Aeris Therapeutics

Aeris Therapeutics is an emerging medical therapeutics company specializing in the development and commercialization of novel treatments for patients with emphysema and other adva...

Altair Therapeutics, Inc.

Based in San Diego, Altair Therapeutics, Inc. is a privately-held biopharmaceutical company developing novel therapeutics to treat human respiratory diseases. Altair Therap...

Vaxiion Therapeutics, Inc.

Vaxiion is dedicated to the design and development of intelligent drug-delivery technologies with special emphasis on targeted oncology therapeutics. Vaxiion Therapeutics was spun...

Click Therapeutics, Inc.

Click Therapeutics, Inc. engineers, validates, and commercializes Digital Therapeutics™ solutions to benefit people with unmet medical needs through cognitive and neurobehavi...

More Information about "Jnana Therapeutics Inc." on BioPortfolio

We have published hundreds of Jnana Therapeutics Inc. news stories on BioPortfolio along with dozens of Jnana Therapeutics Inc. Clinical Trials and PubMed Articles about Jnana Therapeutics Inc. for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of Jnana Therapeutics Inc. Companies in our database. You can also find out about relevant Jnana Therapeutics Inc. Drugs and Medications on this site too.

Advertisement
Quick Search
Advertisement
Advertisement

 

Corporate Database Quicklinks



Searches Linking to this Company Record